Others disagree. Dinesh Abrol, chief scientist at National Institute of Science, Technology and Development Studies in New Delhi, says that the ruling could spur drug companies to adopt new business models focused on radical innovations.
That could affect drug development beyond India’s borders as well, says Tenu Avafia, a senior policy adviser for the United Nations Development Program's HIV Health and Development Practice in New York. The verdict “re-affirms the right of WTO members to implement their patent legislation to meet public-health objectives”, he says. “The implications of the Supreme Court’s decision will be felt across the globe, because the Indian pharmaceutical industry supplies so many low- and middle-income countries with affordable medicines.”